SCHEMBL4807618

SCHEMBL4807618

CCn1cc(Cc2cccc(-c3ccc(OC)cc3C(=O)O)c2)c2ccc(C(=N)N)cc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
RAB9A P51151 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PTPN11 Q06124 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
PLA2G2A P14555 3/20 0.39
F10 P00742 3/20 0.39
F7 P08709 3/20 0.39
F3 P13726 2/20 0.39
F2 P00734 1/20 0.39
PLG P00747 1/20 0.39
SLC22A12 Q96S37 1/20 0.38
MCL1 Q07820 1/20 0.38
BAD Q92934 1/20 0.38
LMNA P02545 1/20 0.36
F11 P03951 3/20 0.36
CYP2C8 P10632 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4815653 0.90 SLC22A12 (0.41) PLA2G2AF10F7F3F2
SCHEMBL4808748 0.86 ALDH1A1 (0.43) ALDH1A1KDM4EHPGDTSHRRAB9A
SCHEMBL4816001 0.82 F10 (0.45) ALDH1A1TSHRRAB9APLA2G2AF10
SCHEMBL4813769 0.81 HDAC1 (0.44) ALDH1A1F10F7SLC22A12MCL1
SCHEMBL4805843 0.81 F2 (0.45) ALDH1A1KDM4EHPGDTSHRRAB9A
SCHEMBL4809426 0.81 PLA2G2A (0.52) ALDH1A1PLA2G2AF10F7F3
SCHEMBL6398608 0.80 F2 (0.47) ALDH1A1KDM4EHPGDTSHRRAB9A
SCHEMBL4811788 0.79 CNR2 (0.41) ALDH1A1KDM4EHPGDTSHRRAB9A
SCHEMBL4813031 0.79 F2 (0.46) ALDH1A1KDM4EHPGDTSHRRAB9A
SCHEMBL6394085 0.79 F2 (0.46) ALDH1A1KDM4EHPGDTSHRRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7417063-B2 Bicyclic heterocycles useful as serine protease inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-08-26 US claimed
US-20050228000-A1 of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent BRISTOL-MYERS SQUIBB COMPANY 2005-10-13 US claimed
US-7417063-B2 Bicyclic heterocycles useful as serine protease inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-08-26 US disclosed
US-20050228000-A1 of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent BRISTOL-MYERS SQUIBB COMPANY 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228000-A1 of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent F12, F11, F2 ALDH1A1 3830/4885KDM4E 316/4885HPGD 3057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.